Treatment of relapsed/refractory MCL

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma with variable clinical behavior.
• Current treatments for relapsed/refractory (R/R) MCL have limitations, especially for patients refractory to Bruton tyrosine kinase (BTK) inhibitors.
• Despite advances, long-term prognosis for R/R MCL remains poor.

Purpose of the Study:

• To review current and emerging treatment options for R/R MCL.
• To highlight the role of combined targeted and immunotherapeutic strategies.
• To discuss novel approaches for patients with limited prognosis.

Main Methods:

• Literature review of current and emerging therapies for R/R MCL.
• Focus on combined targeted treatments (BTK inhibitors, BCL2 inhibitors).
• Exploration of immunotherapeutic approaches (CAR T-cells, bispecific antibodies).

Main Results:

• Targeted and immunotherapeutic approaches are improving outcomes in R/R MCL.
• Combined strategies, including BTK and BCL2 inhibitors, show promise.
• Chimeric antigen receptor T cells and bispecific antibodies represent emerging options.

Conclusions:

• Novel treatment strategies are crucial for improving outcomes in R/R MCL.
• Combination therapies and immunotherapies offer new hope for patients, particularly those with BTK inhibitor resistance.
• Further research into these advanced therapies is warranted to overcome the limitations in long-term prognosis.